Author Login IJIRT Partner Network (IPN) Login

Advancements in Pharmacovigilance and Adverse Drug Reaction Monitoring in 2025

  • Unique Paper ID: 179460
  • Volume: 11
  • Issue: 12
  • PageNo: 6502-6508
  • Abstract:
  • Pharmacovigilance (PV) is critical for ensuring drug safety, particularly with the rise of complex biologics, biosimilars, and pediatric therapeutics in 2025. This review evaluates advancements in PV systems, focusing on pharmacist-led adverse drug reaction (ADR) reporting, clinical decision support systems (CDSS), and big data and artificial intelligence (AI) applications. It also examines PV challenges for biologics and pediatric populations and efforts toward global harmonization. Pharmacists are pivotal in ADR reporting, supported by CDSS for real-time prevention and AI-driven big data for signal detection. However, gaps like underreporting in pediatric PV, alert fatigue in CDSS, and ethical concerns in AI persist. Global initiatives like WHO’s VigiBase aim to standardize reporting, but resource disparities remain. This paper synthesizes recent trends, highlights pharmacists’ evolving roles, and suggests future directions, including integrated mobile apps and enhanced training, to strengthen PV systems for improved patient safety.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 11
  • Issue: 12
  • PageNo: 6502-6508

Advancements in Pharmacovigilance and Adverse Drug Reaction Monitoring in 2025

Related Articles

Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry